Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (111-120 of 241) with videos related to

Pageof 25
Sort By:
Journal of Neurovirology|June 6, 2020
Changes in functional connectivity in people with HIV switching antiretroviral therapySofia Toniolo, Mara Cercignani, Borja Mora-Peris, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
HIV Clinical Trials|August 2, 2012
Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopyJaime H Vera, Lucy J Garvey, Joanna M Allsop, et al.
AIDS (London, England)|February 15, 2021
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudineMark Nelson, Alan Winston, Andrew Hill, et al.
AIDS (London, England)|December 2, 2024
Psychosocial factors account for a proportion of the difference in cognitive performance between persons with and without HIVAnna Jane Dreyer, Celine Le Roux, Kevin G F Thomas, et al.
Antiviral Therapy|April 14, 2010
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patientsLucy Garvey, Ngaire Latch, Otto W Erlwein, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 10, 2021
Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil FumarateLucy Campbell, Birgit Barbini, Keith Burling, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
AIDS (London, England)|December 3, 2019
Defining cerebrospinal fluid HIV RNA escape: editorial review AIDSAlan Winston, Andrea Antinori, Paola Cinque, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2016
Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non-HIV-Related FactorsAli Judd, Marthe Le Prevost, Diane Melvin, et al.
Pageof 25

Showing results (111-120 of 241) with videos related to

Sort By:
Pageof 25
Journal of Neurovirology|June 6, 2020
Changes in functional connectivity in people with HIV switching antiretroviral therapySofia Toniolo, Mara Cercignani, Borja Mora-Peris, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
HIV Clinical Trials|August 2, 2012
Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopyJaime H Vera, Lucy J Garvey, Joanna M Allsop, et al.
AIDS (London, England)|February 15, 2021
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudineMark Nelson, Alan Winston, Andrew Hill, et al.
AIDS (London, England)|December 2, 2024
Psychosocial factors account for a proportion of the difference in cognitive performance between persons with and without HIVAnna Jane Dreyer, Celine Le Roux, Kevin G F Thomas, et al.
Antiviral Therapy|April 14, 2010
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patientsLucy Garvey, Ngaire Latch, Otto W Erlwein, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 10, 2021
Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil FumarateLucy Campbell, Birgit Barbini, Keith Burling, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
AIDS (London, England)|December 3, 2019
Defining cerebrospinal fluid HIV RNA escape: editorial review AIDSAlan Winston, Andrea Antinori, Paola Cinque, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2016
Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non-HIV-Related FactorsAli Judd, Marthe Le Prevost, Diane Melvin, et al.
Pageof 25